Agadir – The Mohammed VI Foundation for Science and Health (FM6SS) and GlaxoSmithKline Maroc SA (GSK Maroc) signed a strategic partnership on Tuesday, in Rabat. The agreement aims to reinforce advancing biomedical research, promoting therapeutic innovation, and improving medical practices across Morocco.
FM6SS plays a leading role at the national level in medical education, research, and healthcare provision, while GSK is one of the world’s major pharmaceutical companies, with a longstanding focus on research and development, particularly in the fields of vaccines and specialized medicines.
The agreement leverages the expertise of the two institutions, seeking to contribute more effectively to public health outcomes and to the continuous modernization of medical knowledge and practice.
The partnership reflects a shared commitment to create a structured framework for cooperation that aligns academic, clinical, and pharmaceutical expertise by combining scientific excellence and the long-term vision of strengthening Morocco’s healthcare system.
According to the terms of the partnership, the two parties will work jointly on a series of structured initiatives organized around defined priority areas.
A central component of the collaboration focuses on capacity building and continuing education for healthcare professionals, through programs designed to support the ongoing development of physicians, pharmacists, and other healthcare practitioners.
These initiatives aim to ensure that medical professionals remain up to date with scientific advances, evolving therapeutic approaches, and internationally recognized clinical standards.
Another key component of the agreement includes the organization of disease awareness initiatives and prevention campaigns within hospital settings, such as pilot projects aimed at enhancing understanding of specific health conditions among both healthcare professionals and patients.
By strengthening awareness and early engagement, the partnership seeks to contribute to improved diagnosis, better patient outcomes, more efficient care pathways and overall quality of care.
The collaboration also places particular importance on the analysis, and responsible use of scientific and medical data. The objective is to improve knowledge of health challenges and support evidence-based medical decision-making in healthcare.
Morocco’s efforts in shaping pharmaceutical progress
In recent years, Morocco has been actively positioning itself as a regional leader in pharmaceutical development and healthcare innovation.
Key policy reforms, including those outlined in the 2026 Finance Bill, have aimed to strengthen domestic pharmaceutical production, reduce the cost of medicines for patients, and enhance the sustainability of the national health system.
Measures such as the drastic reduction of customs duties on medicines and raw materials, from 30 % to approximately 2.5 % for selected products have been designed to boost local manufacturing capacity while ensuring the availability of essential treatments.
These initiatives, coupled with government efforts to modernize regulatory frameworks and promote research and development, have created an environment for partnerships with global pharmaceutical companies.
